FDA approves Agios Pharmaceuticals’ Tibsovo for targeted acute myeloid leukemia treatment

The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals for Tibsovo (ivosidenib), designed for the treatment of acute myeloid leukemia (AML) in patients exhibiting specific genetic mutations and whose condition is either relapsed or refractory. This marks a significant advancement in the targeted therapy landscape for AML.

Tibsovo, an isocitrate dehydrogenase-1 (IDH1) inhibitor, plays a crucial role in combating AML by inhibiting the abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG). This action helps disrupt the growth of malignant cells, offering a strategic approach to treating this aggressive cancer, which typically develops in the bone marrow and leads to an overproduction of abnormal white blood cells.

The FDA’s approval includes the use of Tibsovo alongside a companion diagnostic tool, the RealTime IDH1 Assay, which is crucial for detecting the IDH1 mutation in blood or bone marrow samples. This integration of treatment and diagnostic precision underscores a shift towards more personalized medicine in oncology.

The efficacy of Tibsovo was evaluated in a single-arm trial involving 174 adult patients with relapsed or refractory AML who tested positive for the IDH1 mutation. The study focused on the rates of complete remission (CR) and complete remission with partial hematologic recovery (CRh). Impressively, 32.8% of patients achieved CR or CRh, with these responses lasting a median duration of 8.2 months. Additionally, of the 110 patients requiring blood or platelet transfusions at the start of the trial, 37% went at least 56 days post-treatment without needing further transfusions, indicating a significant reduction in dependency on supportive care.

Richard Pazdur, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products, commented on the approval: “Tibsovo is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH1 mutation. The use of Tibsovo is associated with a complete remission in some patients and a reduction in the need for both red cell and platelet transfusions.”

This approval not only enhances the treatment arsenal available for AML patients but also highlights the importance of targeted therapies that address specific genetic profiles. By focusing on the underlying genetic mutations that contribute to cancer progression, treatments like Tibsovo offer a blueprint for future innovations in oncology.